EGFR T790M Mutation: A Double Role in Lung Cancer Cell Survival?
Open Access
- 1 January 2009
- journal article
- review article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 4 (1), 1-4
- https://doi.org/10.1097/jto.0b013e3181913c9f
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer modelsOncogene, 2008
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATPProceedings of the National Academy of Sciences, 2008
- MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibProceedings of the National Academy of Sciences, 2007
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007
- EGFR-T790M Is a Rare Lung Cancer Susceptibility Allele with Enhanced Kinase ActivityCancer Research, 2007
- Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor SensitivityCancer Cell, 2007
- An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor ReceptorCell, 2006
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004